Compare UTHR & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | COHR |
|---|---|---|
| Founded | 1996 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 21.9B |
| IPO Year | 1999 | 1987 |
| Metric | UTHR | COHR |
|---|---|---|
| Price | $488.92 | $182.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $495.08 | $144.54 |
| AVG Volume (30 Days) | 424.3K | ★ 5.0M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.08 | N/A |
| EPS | ★ 26.38 | 0.76 |
| Revenue | $3,128,400,000.00 | ★ $6,043,358,000.00 |
| Revenue This Year | $13.64 | $17.38 |
| Revenue Next Year | $5.78 | $13.50 |
| P/E Ratio | ★ $18.55 | $238.87 |
| Revenue Growth | 13.50 | ★ 20.80 |
| 52 Week Low | $266.98 | $45.58 |
| 52 Week High | $492.62 | $188.36 |
| Indicator | UTHR | COHR |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 72.40 |
| Support Level | $470.13 | $158.21 |
| Resistance Level | $492.62 | $172.58 |
| Average True Range (ATR) | 10.72 | 10.66 |
| MACD | -0.53 | 2.57 |
| Stochastic Oscillator | 89.55 | 88.52 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.